Toxic epidermal necrolysis medical therapy: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
==Medical Therapy== | ==Medical Therapy== | ||
First | First line: early withdrawal of culprit drugs, early referral and management in burn units or [[intensive care unit]]s, supportive management, nutritional support | ||
Second | Second line: [[intravenous immunoglobulin]] (IVIG) - Uncontrolled trials showed promising effect of IVIG on treatment of TEN; a [[randomized control trial]] is needed in the future to determine the efficacy of IVIG in TEN. | ||
Third | Third line: [[cyclosporin]], [[cyclophosphamide]], [[plasmapheresis]], [[pentoxifylline]], [[N-acetylcysteine]], [[ulinastatin]], [[infliximab]], granulocyte colony-stimulating factors (if TEN associated-leukopenia) | ||
Systemic steroids are unlikely to offer any benefits. | Systemic steroids are unlikely to offer any benefits. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:00, 25 March 2013
|
Toxic epidermal necrolysis Microchapters |
|
Differentiating Toxic Epidermal Necrolysis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Toxic epidermal necrolysis medical therapy On the Web |
|
American Roentgen Ray Society Images of Toxic epidermal necrolysis medical therapy |
|
Risk calculators and risk factors for Toxic epidermal necrolysis medical therapy |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
First line: early withdrawal of culprit drugs, early referral and management in burn units or intensive care units, supportive management, nutritional support
Second line: intravenous immunoglobulin (IVIG) - Uncontrolled trials showed promising effect of IVIG on treatment of TEN; a randomized control trial is needed in the future to determine the efficacy of IVIG in TEN.
Third line: cyclosporin, cyclophosphamide, plasmapheresis, pentoxifylline, N-acetylcysteine, ulinastatin, infliximab, granulocyte colony-stimulating factors (if TEN associated-leukopenia)
Systemic steroids are unlikely to offer any benefits.